Overview

Topical Ionic Contra-Viral Therapy in Actinic Keratosis

Status:
Unknown status
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
To explore the pharmacodynamics and evaluate safety, tolerability and clinical efficacy of ICVT comprised of digoxin and furosemide (dual agent), digoxin (single agent), furosemide (single agent) in patients with AK.
Phase:
Phase 2
Details
Lead Sponsor:
Cutanea Life Sciences, Inc.
Maruho Co., Ltd.
Treatments:
Digoxin
Furosemide